Gene-Editing Firm Mammoth Biosciences Raises $150 Million in Series D Funding Round
For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter. It's completely free and we guarantee you'll learn something new every day.
The past 18 months have generated precious few feel-good headlines in the realm of health. But just because the pandemic has largely dominated news cycles doesn't mean positive developments ceased to exist.
Case in point: the innovation underway at Mammoth Biosciences, where a Nobel laureate-led team is expanding its use of the novel gene-editing tool known as Crispr; developing everything from precise COVID tests to potential cures for genetic diseases.
Source Fool.com
